Found 9 results
Author Title [ Type(Desc)] Year
Filters: Author is Hu, Z  [Clear All Filters]
Journal Article
J. Ledgerwood, DeZure, A., Stanley, D., Novik, L., Enama, M., Berkowitz, N., Hu, Z., Joshi, G., Ploquin, A., Sitar, S., Gordon, I., Plummer, S., Holman, L., ,, Mascola, J., Koup, R., Sullivan, N., and Graham, B., Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report, N Engl J Med, 2014.
J. E. Ledgerwood, Wei, C. J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., ,, Nabel, G. J., and Graham, B. S., DNA Priming and Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials, Lancet Infect Dis, vol. 11, no. 12, pp. 916-924, 2011.
M. Crank, Gordon, I., Yamshchikov, G., Sitar, S., Hu, Z., Enama, M., Holman, L., Bailer, R., Pearce, M., Koup, R., Mascola, J., Nabel, G., Tumpey, T., Schwartz, R., Graham, B., and Ledgerwood, J., Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults, PLoS One, vol. 10, no. 4, p. e0123969, 2015.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., ,, Nabel, G. J., and Graham, B. S., Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect, J Infect Dis, vol. 208, pp. 418-422, 2013.
J. E. Ledgerwood, Costner, P., Desai, N., Holman, L., Enama, M. E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C. A., Sheets, R. A., Koup, R. A., Roederer, M., Bailer, R., ,, Pau, M. G., Sullivan, N. J., Goudsmit, J., Nabel, G. J., and Graham, B. S., A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP is Safe and Immunogenic in Healthy Adults, Vaccine, vol. 29, no. 2, pp. 304-313, 2010.
U. Sarwar, Costner, P., Enama, M., Berkowitz, N., Hu, Z., Hendel, C., Sitar, S., Plummer, S., Mulangu, S., Bailer, R., Koup, R., Mascola, J., Nabel, G., Sullivan, N., Graham, B., and Ledgerwood, J. E., Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial, J Infect Dis, vol. 211, no. 4, pp. 549-557, 2015.
H. Kibuuka, Berkowitz, N., Millard, M., Enama, M., Tindikahwa, A., Sekiziyivu, A., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L., Bailer, R., Koup, R., Nabel, G., ,, Robb, M., and Ledgerwood, J., Safety and Immunogenicity of Ebola Virus and Marburg Virus Glycoprotein DNA Vaccines Assessed Separately and Concomitantly in Healthy Ugandan Adults: A Phase 1b, Randomised, Double-Blind, Placebo-Controlled Clinical Trial, Lancet, vol. 385, no. 9977, pp. 1545-1554, 2015.
L. Chang, Dowd, K., Mendoza, F., Saunders, J., Sitar, S., Plummer, S., Yamshchikov, G., Sarwar, U., Hu, Z., Enama, M., Bailer, R., Koup, R., Schwartz, R., Akahata, W., Nabel, G., Mascola, J., Pierson, T., Graham, B., and Ledgerwood, J., Safety and Tolerability of Chikungunya Virus-Like Particle Vaccine in Healthy Adults: A Phase 1 Dose-Escalation Trial, Lancet, vol. 384, no. 9959, pp. 2046-2052, 2014.